IN idiopathic pulmonary fibrosis, ACE inhibitor use was associated with lower all-cause mortality in propensity matched EHR cohorts. ACE Inhibitor Use and IPF MortalityAngiotensin-converting enzyme (ACE) inhibitors are widely prescribed antihypertensives with established cardioprotective effects. Prior mechanistic and clinical work has raised the possibility that ACE inhibitor therapy could also influence fibrotic pathways, potentially slowing disease progression in idiopathic pulmonary fibrosis (IPF). In a new real-world analysis, ACE inhibitor use was independently associated with improved survival among patients with IPF. In IPF, ACE inhibitor use was associated with lower all-cause mortality (hazard ratio 0.82; 95% CI 0.75–0.91; P≤.001).